Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer

Wright, Alan J.; D’Santos, Paula; Hu, De-en; Hesketh, Richard L.; Lubling, Yaniv; Antunes de Melo Oliveira, Ana Mafalda; Ros, Susana

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Wright, Alan J.
dc.contributor.author	D’Santos, Paula
dc.contributor.author	Hu, De-en
dc.contributor.author	Hesketh, Richard L.
dc.contributor.author	Lubling, Yaniv
dc.contributor.author	Antunes de Melo Oliveira, Ana Mafalda
dc.contributor.author	Ros, Susana
dc.date.accessioned	2021-09-14T11:02:41Z
dc.date.available	2021-09-14T11:02:41Z
dc.date.issued	2020-10-12
dc.identifier.citation	Ros S, Wright AJ, D’Santos P, Hu DE, Hesketh RL, Lubling Y, et al. Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. Cancer Cell. 2020 Oct 12;38(4):516–33.
dc.identifier.issn	1878-3686
dc.identifier.uri	https://hdl.handle.net/11351/6311
dc.description	Inhibició de PI3K-alfa; Càncer de mama; Resposta al tractament
dc.description.sponsorship	This work was supported by a CRUK Programme grant (C197/A28289) and by the CRUK-EPSRC Imaging Centre (C197/A16465), and by NIH grants P30 CA008748 and R01CA190642-01, the Breast Cancer Research Foundation, and by grants from Stand Up To Cancer (Cancer Drug Combination Convergence Team), the V Foundation, and the National Science Foundation.
dc.language.iso	eng
dc.publisher	Cell Press
dc.relation.ispartofseries	Cancer Cell;38(4)
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Mama - Càncer
dc.subject	Medicaments antineoplàstics - Ús terapèutic
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols
dc.subject.mesh	/therapeutic use
dc.title	Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1016/j.ccell.2020.08.016
dc.subject.decs	neoplasias de la mama
dc.subject.decs	protocolos de quimioterapia antineoplásica combinada
dc.subject.decs	/uso terapéutico
dc.relation.publishversion	https://doi.org/10.1016/j.ccell.2020.08.016
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Ros S, Wright AJ, D'Santos P, Hu DE, Hesketh RL, Lubling Y] Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. Cancer Research UK Cambridge Cancer Centre, Cambridge, UK. [Oliveira M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid	32976773
dc.identifier.wos	000581019300012
dc.rights.accessrights	info:eu-repo/semantics/openAccess